Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2024
Deals

Deals report: BridgeBio taps Bayer as EU partner

Plus: Viatris deal extends Idorsia’s runway; AbbVie-OSE; Merck KGaA-C4
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Why predicting responses to checkpoint blockade will take more than just TMB
BioCentury | Aug 30, 2012
Distillery Therapeutics

Indication: Cancer

BioCentury | Feb 13, 2012
Finance

Calculating ChemoCentryx

ChemoCentryx IPO: Autoimmune, cancer play falls short of half-billion valuation
BioCentury | Feb 13, 2012
Clinical News

CCX832: Development discontinued

BioCentury | Feb 7, 2012
Clinical News

ChemoCentryx, GSK discontinue ChemR23 antagonist

BioCentury | Feb 7, 2011
Clinical News

CCX832: Phase I started

BioCentury | Jan 31, 2011
Product Development

Safety in psoriasis

ChemoCentryx hopes CCX832 safer than biologics, older systemics in psoriasis
BioCentury | Apr 22, 2010
Targets & Mechanisms

Promoting pain resolution

BioCentury | Apr 19, 2010
Company News

ChemoCentryx, GlaxoSmithKline deal

Items per page:
1 - 10 of 10